EE200000510A - CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks - Google Patents

CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks

Info

Publication number
EE200000510A
EE200000510A EEP200000510A EEP200000510A EE200000510A EE 200000510 A EE200000510 A EE 200000510A EE P200000510 A EEP200000510 A EE P200000510A EE P200000510 A EEP200000510 A EE P200000510A EE 200000510 A EE200000510 A EE 200000510A
Authority
EE
Estonia
Prior art keywords
monocyte proliferation
promote peripheral
peripheral monocyte
proliferation
utilization
Prior art date
Application number
EEP200000510A
Other languages
English (en)
Estonian (et)
Inventor
Schwarz Herbert
Langstein Joachim
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of EE200000510A publication Critical patent/EE200000510A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
EEP200000510A 1998-07-15 1999-03-05 CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks EE200000510A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15
PCT/EP1999/001440 WO1999044629A2 (de) 1998-03-05 1999-03-05 Verwendung von cd137 zur förderung der proliferation peripherer monocyten

Publications (1)

Publication Number Publication Date
EE200000510A true EE200000510A (et) 2002-02-15

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000510A EE200000510A (et) 1998-07-15 1999-03-05 CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks

Country Status (21)

Country Link
US (1) US6627200B1 (ko)
EP (1) EP1059931B1 (ko)
JP (1) JP2003521439A (ko)
KR (1) KR20010041624A (ko)
AT (1) ATE228371T1 (ko)
AU (1) AU747063B2 (ko)
BR (1) BR9908518A (ko)
CA (1) CA2322684A1 (ko)
CZ (1) CZ20003238A3 (ko)
DE (1) DE59903541D1 (ko)
DK (1) DK1059931T3 (ko)
EE (1) EE200000510A (ko)
ES (1) ES2188140T3 (ko)
HU (1) HUP0102046A3 (ko)
IS (1) IS1986B (ko)
NO (1) NO20004393L (ko)
NZ (1) NZ506695A (ko)
PL (1) PL343427A1 (ko)
PT (1) PT1059931E (ko)
SI (1) SI1059931T1 (ko)
WO (1) WO1999044629A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031474A2 (en) * 2001-10-04 2003-04-17 Herbert Schwarz Cd137 as a proliferation factor for hematopoietic stem cells
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
US20060121030A1 (en) * 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2012043651A1 (ja) * 2010-09-30 2012-04-05 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
US20160030518A1 (en) * 2013-04-03 2016-02-04 The Regents Of The University Of California Compositions and methods for inhibiting viral activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
CA2172165C (en) * 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb
CA2108401A1 (en) * 1993-09-27 1995-03-28 Martin Lotz Receptor induced by lymphocyte activation in imflammatory response

Also Published As

Publication number Publication date
US6627200B1 (en) 2003-09-30
DK1059931T3 (da) 2003-03-24
EP1059931A2 (de) 2000-12-20
JP2003521439A (ja) 2003-07-15
HUP0102046A2 (hu) 2001-10-28
EP1059931B1 (de) 2002-11-27
CZ20003238A3 (cs) 2001-10-17
HUP0102046A3 (en) 2006-02-28
ES2188140T3 (es) 2003-06-16
IS5613A (is) 2000-08-30
IS1986B (is) 2005-02-15
WO1999044629A2 (de) 1999-09-10
PT1059931E (pt) 2003-04-30
SI1059931T1 (en) 2003-04-30
WO1999044629A3 (de) 2000-01-06
AU2932499A (en) 1999-09-20
AU747063B2 (en) 2002-05-09
NZ506695A (en) 2005-01-28
KR20010041624A (ko) 2001-05-25
ATE228371T1 (de) 2002-12-15
BR9908518A (pt) 2000-11-21
DE59903541D1 (de) 2003-01-09
NO20004393D0 (no) 2000-09-04
CA2322684A1 (en) 1999-09-10
NO20004393L (no) 2000-10-31
PL343427A1 (en) 2001-08-13

Similar Documents

Publication Publication Date Title
DE60014966D1 (de) Behandlung zur vermeidung von kalzifizierung für fixierte biomaterialien
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
NO20021281L (no) Vaskul¶r beleggingssammensetning
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE69716525D1 (de) Handgelenkstütze zur Behandlung des Karpaltunnelsyndroms
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
BR9813778A (pt) Utilização de pelo menos um fucano.
DE69033970D1 (de) Huperzin a analoge verbindungen
ATE285177T1 (de) Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen
GB9924957D0 (en) Novel treatment
EE200000510A (et) CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks
DE69624918T2 (de) Verwendung von pseudopterosin zur förderung der wundheilung
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
DE29904177U1 (de) Formstein für das Anlegen von Pflanzbeeten in Hanglagen
IT216863Z2 (it) Guarnizione, per rivestire i bordi di corpi, destinati alla produzione di mobili.